---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-058967"
form_type: "8-K"
ticker: "PMN"
cik: "0001374339"
company_name: "ProMIS Neurosciences Inc."
filed_at: "2026-05-12T10:45:26+00:00"
generated_at: "2026-05-12T10:50:54.550238+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ProMIS Neurosciences Q1 net loss $8.2M; PRECISE-AD interim analysis expected early Q3 2026

## Summary
- Net loss of $8.2M for Q1 2026, vs $7.3M in Q1 2025; cash & equivalents $63.8M as of March 31.
- Closed $75.5M PIPE in Feb 2026; up to $100M additional from warrant exercises; funds operations through 2027.
- PRECISE-AD Phase 1b fully enrolled (144 participants); blinded 6-month interim analysis anticipated early Q3 2026.
- Unblinded 12-month top-line data expected early 2027; subcutaneous formulation development accelerated.
- Lead candidate PMN310 selectively targets toxic amyloid-beta oligomers, aiming to improve safety vs plaque-directed antibodies.

## SEC filing metadata
- accession: 0001104659-26-058967
- form_type: 8-K
- ticker: PMN
- cik: 0001374339
- company_name: ProMIS Neurosciences Inc.
- filed_at: 2026-05-12T10:45:26+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1374339/000110465926058967/0001104659-26-058967-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1374339/000110465926058967/pmn-20260512x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-058967
- JSON: https://secwatch.observer/filing/0001104659-26-058967.json
- Plain text: https://secwatch.observer/filing/0001104659-26-058967.txt

## Key facts
- Earnings Releases
  ProMIS Neurosciences Inc. reported financial results for quarter ended March 31, 2026.
  - Period: quarter ended March 31, 2026
  - Result: reported results
  source text: reporting its financial condition and financial results as of and for the quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1374339/000110465926058967/0001104659-26-058967-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.